5 Cash-Rich Dividend Stocks to Invest In Right Now

3. McKesson Corporation (NYSE:MCK)

Operating Cash Flow (TTM): $10.48 Billion

On April 8, Evercore ISI lowered its price recommendation on McKesson Corporation (NYSE:MCK) to $950 from $1,000. It reiterated an Outperform rating on the shares. The changes came as part of its Q1 preview for healthcare technology and distribution, along with updates to its Tactical call lists. As part of those moves, the firm also added McKesson to its “Tactical Underperform” list.

A couple of days earlier, on April 6, BofA analyst Allen Lutz reduced his price target to $1,000 from $1,040 while maintaining a Buy rating. He pointed to the rapid decline in cash-pay GLP-1 prices as a key factor. He said the shift toward cash-pay prescriptions for Wegovy and Zepbound could weigh on McKesson’s FY27 EBIT outlook in its Prescription Technology Solutions segment. In his view, this trend may cause results to come in below Street expectations.

McKesson Corporation (NYSE:MCK) operates as a diversified healthcare services company focused on improving patient outcomes. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter drugs, along with other healthcare-related products across the United States.